Cargando…

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P‐glycoprotein (P‐gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)‐acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faessel, Hélène, Nemunaitis, John, Bauer, Todd M., Lockhart, A. Craig, Faller, Douglas V., Sedarati, Farhad, Zhou, Xiaofei, Venkatakrishnan, Karthik, Harvey, R. Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595297/ https://www.ncbi.nlm.nih.gov/pubmed/30845347 http://dx.doi.org/10.1111/bcp.13915

Ejemplares similares

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
por: Faessel, Hélène M., et al.
Publicado: (2019)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial
por: Zhou, Xiaofei, et al.
Publicado: (2021)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
por: Handa, Hiroshi, et al.
Publicado: (2022)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
por: Swords, R T, et al.
Publicado: (2017)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
por: Gupta, Neeraj, et al.
Publicado: (2017)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway
por: Xu, Junfeng, et al.
Publicado: (2022)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
por: Voss, Martin H., et al.
Publicado: (2020)

Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors
por: Patel, Chirag, et al.
Publicado: (2020)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022)

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
por: Nemunaitis, John, et al.
Publicado: (2012)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma
por: Benamar, Mouadh, et al.
Publicado: (2016)

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2021)

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2022)

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2022)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kk69j3d1f25utqfgq9bnsghumo